EGFR and colorectal cancer: We then decided to investigate the correlation between both FISH and CISH EGFR GCN and clinical outcome in terms of response rate and time to progression (TTP) in irinotecan-refractory K-RAS wild-type colorectal cancer patients treated with irinotecan-cetuximab.